瑞银首次覆盖联邦制药(03933.HK) ，予“买入”评级，目标价18.9元。公司是中国领先的药品制造商，拥有整合的业务线，涵盖中间产品与原料药，以及制剂产品，分别占2024年收入74%及26%。凭借数十年在代谢疾病领域的研发专业与强劲的早期临床结果，公司于去年3月将UBT251在中国以外的权益授权予诺和诺德(NVO.US) ，协议包括2亿美元的首付款、最高达18亿美元的里程碑付款以及分层销售...
Source Link瑞银首次覆盖联邦制药(03933.HK) ，予“买入”评级，目标价18.9元。公司是中国领先的药品制造商，拥有整合的业务线，涵盖中间产品与原料药，以及制剂产品，分别占2024年收入74%及26%。凭借数十年在代谢疾病领域的研发专业与强劲的早期临床结果，公司于去年3月将UBT251在中国以外的权益授权予诺和诺德(NVO.US) ，协议包括2亿美元的首付款、最高达18亿美元的里程碑付款以及分层销售...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.